Microwave ablation plus lenvatinib for recurrent liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hepatocellular carcinoma that started in the liver (not another primary cancer).
- Your liver cancer has come back, and you have not had any tumor-related treatment yet for this recurrence.
- You have 3 or fewer tumors, and each tumor is 5 cm or smaller.
- Your overall health is good (KPS 90 or higher), and you are age 18 to 75.
- Your liver function is Child-Pugh A or B (B score must be 7 or less).
- Recent blood tests show adequate blood counts and organ function (meeting lab thresholds the study lists).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
This trial compares two treatments for people whose liver cancer has come back (recurrent intermediate-stage hepatocellular carcinoma). One group gets TACE plus lenvatinib (a targeted therapy), the other gets TACE plus lenvatinib plus ablation (a procedure that destroys tumors with heat or cold). The goal is to see which combination works better.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This study combines microwave ablation, which uses heat to destroy cancer cells, with immune cell therapy that boosts your body's natural defenses to fight the cancer. It may help people with early-stage liver cancer who cannot have surgery.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.